| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 6.527 | 9.888 | 0 | 0 | 0 | 0 | 0 | 24.158 | 27.655 | 29.388 |
| Total Income - EUR | 6.527 | 9.888 | 0 | 0 | 0 | 0 | 0 | 24.158 | 27.655 | 29.388 |
| Total Expenses - EUR | 1.950 | 2.500 | 1.083 | 76 | 75 | 149 | 91 | 7.898 | 9.213 | 11.298 |
| Gross Profit/Loss - EUR | 4.577 | 7.388 | -1.083 | -76 | -75 | -149 | -91 | 16.260 | 18.442 | 18.090 |
| Net Profit/Loss - EUR | 4.381 | 7.092 | -1.083 | -76 | -75 | -149 | -91 | 15.823 | 18.171 | 17.802 |
| Employees | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Nadalis Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.020 |
| Current Assets | 4.589 | 11.497 | 8.006 | 3.089 | 214 | 61 | 60 | 17.395 | 22.685 | 23.399 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 382 | 1 | 1 | 1 | 1 | 1 | 1 | 10.597 | 12.600 | 26 |
| Cash | 4.206 | 11.496 | 8.005 | 3.088 | 213 | 61 | 59 | 6.798 | 10.085 | 23.373 |
| Shareholders Funds | 4.426 | 11.472 | 3.224 | 3.089 | 214 | 61 | -31 | 15.791 | 18.219 | 23.416 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 163 | 24 | 4.783 | 0 | 0 | 0 | 91 | 1.604 | 4.466 | 1.004 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4719 - 4719" | |||||||||
| CAEN Financial Year |
4719
|
|||||||||
Comments - Nadalis Med Srl